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Dihydropyrim idine dehydrogenase (DPD) is responsible for the breakdown of the widely used anti- 
neoplastic agent 5-flu or our a cil (5-FU ), thereby lim iting the efficacy o f the therapy. It has been sug­
gested that patients suffering from  5-FU toxicities due to a low activity o f D PD  are genotypically 
heterozygous for a m utant allele o f the gene encoding D PD , In this study we investigated the cDNA 
and a genom ic region o f the D P D  gene of a cancer patient experiencing severe toxicity following 5-FU 
treatm ent for the presence o f m utations. Although norm al activity o f DPD was observed in fibro­
blasts, the D PD  activity in leucocytes of the cancer patient proved to be in the heterozygous range. 
Analysis o f the D P D  cDNA showed heterozygosity for a 165 bp deletion that results from exon skip­
ping. Sequence analysis o f the genom ic region encom passing the skipped exon showed that the tumour 
patient was heterozygous for a G—>A point m utation in the invariant GT splice donor sequence in the 
intron downstream  o f the skipped exon. So far, the G-^A point m utation has also been found in 8 out 
of 11 patients suffering from  a com plete deficiency o f D P D . Considering the frequent use o f 5-FU in 
the treatm ent o f cancer patients, the severe 5-FU -r elated toxicities in patients with a low activity of 
D PD  and the high frequency o f the G-~>A m utation in D PD  deficient patients, analysis o f the DPD  
activity and screening for the G—*A m utation should be routinely carried out prior to the start of the 
treatm ent with 5-FU , ©  1997 E lsevier Science Ltd-
Key words: dihydropyrim idine dehydrogenase, 5-fluorouracil, exon skipping, cardiotoxicity, hyper­
pigm entation
Eur J  Cancer, Vol. 33, No. 13, pp. 2258-2264, 1997
INTRODUCTION
D i h y d r o p y r i m i d i n e  d e h y d r o g e n a s e  (DPD* EC 1.3.1.2) is
the initial and rate-limiting enzyme in the catabolism of the 
pyrimidine bases and it catalyses the reduction of thymine 
and uracil to 5,6-dihydrothymine and 5,6-dihydrouracil* 
respectively. In children* the deficiency of DPD is often 
accompanied by a neurological disorder but a considerable 
variation in the clinical presentation among these padents has 
been reported [1], In these patients* a large accumulation of 
uracil and thymine has been detected in urine* blood and in
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cerebrospinal fluid [1-3]. Recently* we provided the first evi­
dence at the molecular level that the mRNA of a patient with 
a deficiency of dihydropyrimidine dehydrogenase lacked a 
segment of 165 nucleotides that results from exon skipping 
with the splicing error being caused by a point mutation in an 
invariant GT splice donor sequence in the intron downstream 
of the skipped exon [4-6].
DPD is also responsible for the breakdown of the widely 
used antineoplastic agent 5-fluorouracil (5-FU)* thereby limit­
ing the efficacy of the therapy. 5-FU is one of the few drugs 
that shows some antitumour activity against various other­
wise untreatable tumours including carcinomas of the gas­
trointestinal tract, breast* ovary and skin. Although the
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cytotoxic effects of 5-FU are probably directly mediated by 
the anabolic pathways, the catabolic route plays a sig­
nificant role since more than 80% of the administered 5- 
FU is catabolised by DPD [7]. Indeed, inhibitors of DPD  
have been shown to potentiate die effect of 5-FU in vitro 
and in vivo [8- 10].
The important role of DPD in chemotherapy with 5-FU  
has been shown in cancer patients with a complete or near- 
complete deficiency of this enzyme. These patients suffered 
from severe (neuro) toxicity, including death, following 5-FU 
chemotherapy [11-19], including 2 cancer patients with a 
complete deficiency of DPD [12,13], 3 patients with a sus­
pected deficiency of DPD [11,15] and 13 patients with a very 
low activity of DPD [14,16-19]. A clinical pharmacological 
study of one of these patients with a complete deficiency of 
DPD demonstrated minimal catabolism of 5-FU with a 10- 
fold longer 5-FU half-life compared with patients with a 
normal activity of DPD [12].
It has been suggested that patients suffering from 5-FU 
toxicities due to a low activity of DPD are genotypically het­
erozygous for a mutant allele of the gene encoding DPD [20]. 
Furthermore, the frequency of heterozygotes in the normal 
population has been estimated to be as high as 3% [20-23]. 
So far, heterozygosity for a mutated DPD allele has only been 
shown in 1 cancer patient [24]. In this paper, we demonstrate 
that a patient experiencing severe toxicity following 5-FU  
chemotherapy proved to be heterozygous for a G—>A point 
mutation in an invariant GT splice donor sequence, leading 
to faulty splicing. Furthermore, the G—>A point mutation has 
also been found in 8 out of 11 other patients suffering from a 
complete DPD deficiency.
MATERIALS AND METHODS
Materials
AmpliTaq Taq polymerase was supplied by Perkin-Elmer 
(San Jose, California, U.S.A.). A Qiaquickspin PCR pur­
ification kit was obtained from Qiagen (Hilden, Germany). 
Dye-primer cycle-sequence-ready reaction kits were obtained 
from Applied Biosystems (San Jose, California, U.S.A.). Oli­
gonucleotides were synthesised on a Millipore Expedite oli­
gonucleotide synthesiser. HAM-F10 culture medium, fetal 
calf serum and newborn calf serum were obtained from 
Gibco Laboratories (Paisley, Scotland). [2- I4C]Thymine was 
obtained from Biotrend GmbH (Koln, Germany). Lympho- 
paque was obtained from Nyegaard & Co (Oslo, Norway). 
LeucoSep tubes were supplied by Greiner (Frickenhausen, 
Germany). All other chemicals were of analytical grade.
Culture conditions of the human fibroblasts
Fibroblasts were cultured from skin biopsies obtained from 
controls (healthy volunteers and patients admitted to our 
hospital with clinical and biochemical findings not indicative 
of inborn errors in the purine and pyrimidine metabolism, 
mitochondrial oxidative phosphorylation or disorders in the 
urea cycle), patients with a DPD deficiency and obligate het­
erozygotes (e.g. parents of the affected family member).
Biopsies were incubated at 37° C in HAM-F10 medium 
supplemented with 20 mM HEPES and 20% (v/v) fetal calf 
serum in 25 cm2 cell-culture flasks until an adequate number 
of proliferating cells was obtained. Subsequently, the cells 
were harvested with 0.25% (w/v) trypsin and distributed over 
two 75 cm2 flasks. These cells were cultured in HAM-F10 
medium supplemented with 20mM HEPES and 15% (v/v)
newborn calf serum. Monolayers of fibroblasts were grown to 
confluency and harvested with 0.25% (w/v) trypsin. After 
washing the cells twice with PBS (9,2 mM Na2HP04, 
1.3 mM NaH2PÜ4 and 140mM  NaCl, pH 7.4) and once 
with 0.9% (w/v) NaCl, the cells were collected by cen- 
ation (17 5 g y for 5min) and the supernatant was dis­
carded. The pellets were stored ar — 80° C.
Isolation of human leucocytes
Leucocytes were isolated from 15 ml EDTA-antic- 
oagulated blood using lymphopaque (spec, gravity 1.086 g/ 
ml, 350m 0sm ). The blood sample (± 7 ml) was layered on 
3 ml of lymphopaque using 10 ml LeucoSep tubes and cen­
trifuged at 800 £ at room temperature for 2 0 min. The inter­
face containing the leucocytes was collected, diluted with 
phosphate-buffered saline (PBS; 9.2 mM Na2HP04 , 1.3 mM 
NaH2P 0 4 and 140 mM NaCl, pH 7,4) to a final volume of 
approximately 12 ml and centrifuged at 800 £ for 8min. To 
lyse the erythrocytes, the pellet was resuspended in 5 ml ice- 
cold ammonium chloride solution (8 .29g/l N H 4CI, 1 ,00g/1 
KHCO3 and 37 .2mg/1 EDTA) and kept on ice for 5min. 
After the addition of 7 ml ice-cold PBS, the solution was 
centrifuged at 250^ at 4°C for 8 min. This step was repeated 
twice to remove the platelets. The resulting pellet was resus­
pended in 3 ml PBS and an aliquot was used for cell counting 
and for a differential count to determine the purity o f the 
leucocyte pellet. The remaining suspension was centrifuged 
at 1 1 0 0 0 ^ at 4°C for 10 s. The supernatant was discarded 
and the pellet was frozen in liquid nitrogen and stored at 
—80aC until further analysis.
Preparation of fibroblast and leucocyte homogenates
The frozen cell pellets of fibroblasts and leucocytes were 
suspended in 300 jjl 35 mM potassium phosphate (pH 7.4) 
and 2.5 mM MgCl2 and sonicated three times at 4W (Vibra- 
cell Sonificator, output control 20%) for 10 s with intervals of 
30 s under constant cooling in ice-water. After centrifugation 
(11 000£ at 4°C for 20 min), the supernatants were removed 
and saved for further analysis at — 80°C. Protein concentra­
tions in the supernatants were determined with a copper- 
reduction method using bicinchoninic acid, essentially as 
described by Smith and associates [25].
Determination of dihydropyrimidine dehydrogenase activity 
The activity of dihydropyrimidine dehydrogenase was 
determined in a reaction mixture containing 35 mM potas­
sium phosphate (pH 7.4), 1 mM dithiothreitol, 2.5 mM MgCl2, 
250 jiM NADPH and 25)iM  [14C] thymine. Separation of 
radiolabelled thymine and the reaction product dihydro­
thymine was performed isocratically (50 mM NaH2P 0 4 (pH 
4.5) at a flow rate of 2 ml/min) by reversed-phase HPLC on a 
Supelcosil LC-18-S column (250x4.6 mm, 5 jim particle 
size) with on-line detection of radioactivity [26].
Isolation of R N A  and D N A
RNA and D N A  were isolated from cultured fibroblasts by 
the guanidinium thiocyanate method [27] and standard pro­
cedures [28], respectively.
PCR analysis
cDNA synthesis and RT-PCR reactions for amplifying 
cDNA coding for DPD were carried out essentially as 
described before [4 ,6]. Four overlapping DPD cDNA
a
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fragments were amplified using primer sets as specified in 
Table 1. Forward primers had an 5'-TGTAAAAC- 
GACGGCCAGT-3/ extensions whereas reverse primers had 
an 5 '-C A G G A A A C A G C T A T G A C C -3 f extension at their 
5/-ends. These sequences are complementary to the labelled 
M13 and M l 3 reversed primers used in the dye-primer 
sequence reaction. Amplification was carried out in 50jal 
reaction mixtures containing lOmM Tris-HCl (pH 8.3), 
50 mM KC1, 3 mM MgCl2, 1 |iM of each primer and 0.2 raM 
dNTPs. After initial denaturation for 5min at 95° C, 2 U  of 
Taq polymerase was added and amplification carried out for 
30 cycles (1 min 95° C3 1 min 65° C, 1 min 72° C).
Amplification of the genomic region containing a DPD  
exon and its flanking sequences was carried out essentially as 
described before with the primers Ii and I2 [6]. These pri­
mers also contained the above-mentioned 5'-extensions for 
sequencing purposes. PCR products were separated on 1% 
agarose gels, visualised with ethidium bromide and purified 
using a Qiaquickspin PCR purification kit and used for direct 
sequencing.
Sequence analysis
Sequence analysis was carried out on a Applied Bio systems 
model 377 automated D N A  sequencer using dye-primer 
method for the DPD cDNA and genomic fragments.
Statistical analysis 
The differences between the mean activity of DPD in 
fibroblasts of controls and obligate heterozygotes were ana­
lysed with the two-sample r-test using log transformed data. 
Similar results were obtained with analysis by the non-para- 
metric Mann-Whitney test of the original data. The level of 
significance was set a priori at P  <  0.05. Analyses were per­
formed with the Statistical Package for the Social Sciences 
(SPSS Inc. Chicago, Illinois^ U.S.A.).
RESULTS
Clinical evaluation 
The patient is a female (4-3-1931) who was treated for 
hyperthyroidism (Graves' disease) with thyrostatics and 
radioactive iodine in 1981. Subsequently she developed 
a hypothyroidism for which she was treated with L-thyrox- 
ine. She was known to be hypertensive and the treatment
modality consisted of protracted use of propranolol and 
dytenzide.
In December 1989s a mastectomy was performed due to 
an infiltrative ductal carcinoma in her right breast which was 
partly of the lobular type and manifested as Paget's disease. 
Postoperative staging showed pT4 with metastases in two of 
the 19 removed axillary lymph nodes with extranodal growth. 
The patient received radiation on the thorax, axillary lymph 
nodes and supraclavicular lymph nodes. Investigation of the 
tumour tissue showed the presence of oestrogen and proges­
terone receptors. After local and regional treatment, adjuvant 
chemotherapy started on 9 April 1990, with tamoxifen 
(20 mg) to be administered twice daily for 2 years, 3-amino- 
1-hydroprolylildene bisphosphonate (150 mg) twice a day 
and 5-FU (15 mg/kg) to be administered intravenously every 
week. The first two injections with 900 mg 5-FU were toler­
ated well by the patient without complications. However, one 
day after the third intravenous injection with 5-FU she 
developed a serious diarrhoea without blood and suffered 
from nausea and vomiting. Physical examination showed 
dehydration and a diffuse sensitive abdomen, whereas no 
abnormalities of the mouth and throat were observed. Fur­
thermore, the liver and spleen were not enlarged. She was 
slightly hypotensive (110/70 mmHg) accompanied with an 
increased pulse rate. Nine days after admission of the third 
5-FU injection, severe hypokalaemia (2.1 mmol/1), hypona- 
traemia (127mmol/1) and leucopenia (1 .6 x l0 9/l) with a 
normal number of thrombocytes (1 9 9 x l0 9/l) was observed. 
The next day, the number of leucocytes and thrombocytes 
decreased further to 0 .9 x l0 9/l and 1 6 2 x l0 9/l, respectively. 
During this period the patient developed fever (39°C). 
Since examination of urine, stools and sputum revealed no 
indication for infectious agents, treatment consisted of 
administration of liquid and supplementation of minerals. 
Her body temperature fell spontaneously and therefore no 
antibiotics were administered. During the subsequent days 
the clinical picture and haematological parameters gradually 
improved and normalised.
A conspicious pigmentation of the operation scar and lines 
of the hands was also observed which disappeared during 
subsequent weeks. Furthermore, it should be noted that 
ECGs made on 26 April and 2 May 1990, showed extreme T  
wave inversions reflecting 5-FU-associated cardiotoxicity
Table 1. Oligonucleotides for DPD genomic and RT—PCR
Primer Sequence 5' 3/ Direction Position
Af CTCGAGACTGTAGGCACTGCCA Sense 61-82*
Ar TCATACGGCAGCCGGAACTGAGG Anti sense 775-797*
Bf T G C T T C C T T T T T G G C T C  GATTGGG Sense 687-710*
Br CGGCCATTTCTACACTAATGTCCACC Antisense 1671-1696*
Cf AT C G G T GAATGAT GGAAAGC AAGC Sense 1554-1577*
Cr AGCC AAAATGGGA AATC C AGGCAG Antisense 2434-2457*
Df CCAGCAGTGGGGATTGCAAAGC Sense 2335-2356*
D r TTGGAAAGAGCTGAACACAAGGATC Antisense 3226-3250*
Ii T C  C TC T G  C AAAAATGTG AG AAGGGAC C Sense 451-477f
I2 TCACCAACTTATGCCAATTCTC Anti sense 762-7831
^Numbering according to the DPD  cDNA sequence as published by Yokota and associates [29]. fNumbering according to the intron 
sequences flanking the DPD exon as published by Vreken and associates [6].
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when compared to ECGs made in October 1989 and May 
1991. The observed cardiotoxicity reflects an increased cor­
onary insufficiency in this patient who is familiar with 
coronary artery disease for which she underwent a by-pass 
operation in 1986.
Due to the excessive toxicity following the administration 
of 2700 mg 5-FU in 2 weeks, no further treatment with 5-FU 
was administered. The treatment with tamoxifen was con­
tinued up to 9 April 1992. Up to now, the patient is in good 
health with no evidence of recurrent cancer.
To investigate whether the excessive toxicity following the 
administration of 5-FU might have been caused by a com­
plete deficiency of DPD, urine was collected on 9 May 1990. 
However, no abnormalities were observed in the concentra­
tion of uracil and thymine.
Activity of DPD in leucocytes and fibroblasts
To investigate whether the severe fluorouracil toxicity in 
this patient might have been caused by a near-complete defi­
ciency of DPD, we determined the activity of DPD in leuco­
cytes and in cultured fibroblasts established from a skin 
biopsy. Figure 1 shows that the mean activity of DPD in 
fibroblasts of controls of 0.89 (±0.56, S.D.) nmol/mg/h is 
significantly higher (P= 0.002) than that of 0.26 (±0.20, 
S.D.) nmol/mg/h observed in fibroblasts of obligate hetero­
zygotes. In patients suffering from a complete deficiency of 
DPD, the activity proved to be undetectably low. Surpris­
ingly, the activity of DPD in fibroblasts of the tumour patient 
(1.1 nmol/mg/h) was within the range of the controls and 
above the upper limit of the range of DPD activities as 
observed for the obligate heterozygotes (0.06-0.66 nmol/mg/ 
h). In contrast, in leucocytes the activity of DPD of the 
tumour patient (3.1 nmol/mg/h) was decreased compared to 
the mean activity of DPD of controls (9.6 nmol ± 3.7 nmol/ 
mg/h) and was comparable to that observed for obligate het- 
erozygotes (Figure 2).
R T —PCR analysis of DPD mRNA in cultured fibroblasts
Total RNA isolated from fibroblasts of the tumour patient 
and controls was subjected to RT-PCR and the coding 
sequence of the DPD cDNA was fully amplified in four frag­
ments that span 737 bp (fragment A), 1010 bp (fragment B), 
904 bp (fragment C) and 916 bp (fragment D) (Figure 3, 
upper panel). Analysis of the PCR fragments by gel electro­
phoresis showed normal sized fragments A, B and D in all
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Figure 1, DPD activity in fibroblasts. The m ean activities of 
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Figure 2. D PD  activity in  leucocytes. The m ean activity of
DPD in controls is indicated by a solid line.
subjects (results not shown). However, the 904bp fragment 
C was found together with a smaller sized fragment of 739 bp 
in the tumour patient, whereas only the normal sized 904 bp 
fragment was detected in a control subject (Figure 3, lower 
panel). For comparison, we also included the analysis of the 
904 bp fragment in a Finnish paediatric patient suffering from 
a DPD deficiency (subject 2) who proved to be homozygous 
for the smaller sized fragment, whereas his father (subject 1) 
proved to be heterozygous for the predicted normal-sized 
fragment and the smaller-sized fragment.
Sequence analysis of the PCR fragments showed that 
the 739 bp fragment originated from the 904 bp fragment 
by a deletion of 165 bp which proved to be identical to the 
deletion described previously in two unrelated Dutch patients
[4-6].
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Figure 3. Amplification o f D PD  mRNA by RT-PCR and ana­
lysis by gel electrophoresis. The sequence o f the cDNA coding 
for D PD  was fully amplified in  four fragm ents (a), (b) shows 
the analysis o f the C fragment from  a control, the 5-FU 
patient, a paediatric D PD  patient (subject 2) and his father 
(subject 1). The 904bp and 739bp bands correspond to the 
wild-type and the deleted cDNA fragm ents, respectively. The 
sizes o f the three bands present in the marker lane are 947 bp, 
831 bp and 564 bp, respectively. A plus indicates the presence 
o f  the wild-type allele and a m inus indicates the presence of
the m utant allele.
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Genomic sequence analysis 
In order to identify the genomic mutation leading to the 
observed exon skipping in our patients, two intron specific 
primers were used for amplification of the complete exon and 
the upstream and downstream intron sequences [6]> 
Sequence analysis showed that the tumour patient proved to 
be heterozygous for a G—►A point mutation in the invariant 
GT splice donor sequence in the intron downstream of the 
skipped exon (Figure 4(b)), whereas a normal conserved GT 
splice donor site was observed in the control (Figure 4(d)). 
The paediatric patient suffering from a DPD deficiency 
proved to be homozygous for the G—>A mutation thereby 
changing the invariant splice donor site GT into AT 
(Figure 4(a)), whereas his father proved to be heterozygous 
for this type of mutation (Figure 4(c)).
DISCUSSION
We have provided unambiguous evidence at the molecular 
level for heterozygosity of a mutated allele of the gene 
encoding DPD in a tumour patient suffering severe toxicity 
after administration of 5 -F U  Although haematological (leu- 
copenia) and gastrointestinal toxicities (nausea., vomiting, 
diarrhoea) are common si de-effects of 5-FU, the occurrence 
of hyperpigmentation and cardiotoxicity are rarer side-effects 
[30-32]. Hyperpigmentation and cardiotoxicity are more 
often observed after protracted infusion of 5-FU when com-
(a) (b)
A C A A C
*■ intron
A T A A G T G T G A  A C A A C
----- ► intron
R T A A G T G T G A
(c) <d)
C v v
A C A A C
intron
R T A A G T G T G A  A C A A C
*- intron
G T A A G T G T G A
Figure 4. Sequence analysis o f the intron-exon boundary. A 
genomic DNA fragment spanning the D PD  exon and its 
flanking sequences was amplified and used for direct sequence 
analysis, (a) Paediatric D PD  patient (subject 2); (b) 5-FU  
patient] (c) father o f the paediatric patient (subject 1); (d) 
control. The sequence depicted below each panel shows the 
last five nucleotides o f the exon (ACAAC) followed by the first 
10 nucleotides o f the intron. In the paediatric DPD patient, 
homozygosity for a G—>A point mutation in the first nucleotide 
of the downstream intron (indicated by an arrow) is shown. 
The father o f the paediatric patient and the 5-FU patient are 
heterozygotes for this m utation, since both G and A are pres­
ent in this position.
pared to bolus injections, as a result of the extended infusion 
of this drug [30-32]. Thus, the occurrence of these types of 
toxicities in our patient might be related to increased 5-FU 
levels due to a decreased activity of DPD. Furthermore, our 
patient might be especially prone to the development of 
5-FU-associated cardiotoxicity since she is familiar with cor­
onary artery disease [32].
Surprisingly, determination of the activity of DPD in 
fibroblasts of the 5-FU patient showed normal activity of 
DPD, which was within the range of controls and outside the 
range of DPD activities as observed for obligate hetero­
zygotes. Although fibroblasts are a very suitable type of tissue 
to establish a complete deficiency of DPD, the overlapping 
range in DPD activities between controls and obligate het­
erozygotes precludes unambiguous detection of hetero­
zygotes. It is now well established that the activity of DPD is 
generally lower in proliferating (malignant) cells than in rest­
ing (differentiated) cells [33-35]. Therefore, a conceivable 
possibility for the large range of DPD activities in fibroblasts 
might be that the activity of DPD is influenced by the degree 
of confluency of these fibroblasts. A similar phenomenon has 
been observed for lysosomal enzyme activities which proved 
to vary during the various growth phases of human fibroblasts 
[36]. In that respect, we and others have shown that carrier 
detection of a deficiency of DPD can be performed by deter­
mination of the DPD activity in peripheral mononuclear cells 
[13, 24,37]. Analysis of the activity of DPD in the leucocytes 
of the cancer patient demonstrated that the activity of DPD 
was comparable to that observed in other obligate hetero­
zygotes. Furthermore, the residual activity of DPD in the leuco­
cytes of the cancer patient (32% of the mean DPD activity of 
leucocytes obtained from healthy donors) is comparable to that 
observed in other patients suffering from 5-FU toxicities [17].
Although the activity of DPD can be detected in a variety 
of human tissues^ it should be borne in mind that the majority 
of the DPD activity, and therefore the catabolism of 5-FU, is 
confined to the liver [38,39]. Lu and associates showed in 2 
cancer patients suffering from a partial DPD deficiency that 
the decreased activity of DPD in peripheral mononuclear 
cells was paralleled by a decreased activity of DPD in the liver 
as well [17]. Therefore, they suggested that the activity of 
DPD in peripheral mononuclear cells could be used as a 
marker for DPD activity in general. However, Stephan and 
associates reported a patient with a disease-related liver 
impairment who suffered from severe toxicities after admin­
istration of 5-FU due to a decreased activity of DPD in liver, 
whereas a normal activity of DPD in lymphocytes was 
observed [18],
The G—>A point mutation changes an invariant GT splice 
donor site into AT which, apparently, leads to skipping of a 
165 bp exon immediately upstream of the mutated splice 
donor site during the splicing of DPD pre-mRNA. As a con­
sequence, a 165 bp fragment encoding the amino acid resi­
dues 581-635 of the primary sequence of the DPD protein is 
lacking in the mature DPD mRNA [4-6]. So far, the analysis 
of 11 patients with a complete deficiency of DPD revealed 
homozygosity for the G—»A point mutation in 6 patients from 
Denmark, Finland and The Netherlands and heterozygosity 
for this mutation in 2 patients ([5,6]; data not shown). The 
apparent high frequency of this mutation among patients with 
a complete deficiency of DPD supports the observation that 
there is some kind of homogeneity for this mutation in 
Northern Europe [24],
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Although analysis of the DPD activity in 124 healthy sub­
jects [17] and 185 cancer patients [23] did not reveal patients 
with a complete deficiency of DPD, a number of patients 
have been found with low activities of DPD experiencing 
increased toxicities, including death, following 5-FU treat­
ment [17], In this respect, the frequency of patients who are 
heterozygous for a mutated DPD allele has been estimated 
to be as high as 3% [20-24]. Considering the frequent use of 
5-FU in the treatment of cancer patients, the severe 5-FU- 
related toxicities in patients with a low activity of DPD and 
the high frequency of the G—>A mutation in DPD deficient 
patients, analysis of DPD activity in leucocytes and screening 
for the G — mutation should be routinely carried out prior 
to the start of the treatment with 5-FU. Fortunately, the 
G—>A point mutation destroys a unique M aell restriction site 
present in an amplified genomic DNA fragment encompass­
ing the slapped exon and its flanking sequences, allowing the 
rapid screening of this mutation in patients [6]. The preva­
lence of this mutation in cancer patients is currently under 
investigation in our laboratory.
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